288 related articles for article (PubMed ID: 20194867)
1. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis.
Feldman DR; Sheinfeld J; Bajorin DF; Fischer P; Turkula S; Ishill N; Patil S; Bains M; Reich LM; Bosl GJ; Motzer RJ
J Clin Oncol; 2010 Apr; 28(10):1706-13. PubMed ID: 20194867
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors.
Kondagunta GV; Bacik J; Sheinfeld J; Bajorin D; Bains M; Reich L; Deluca J; Budnick A; Ishill N; Mazumdar M; Bosl GJ; Motzer RJ
J Clin Oncol; 2007 Jan; 25(1):85-90. PubMed ID: 17194908
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study.
Selle F; Wittnebel S; Biron P; Gravis G; Roubaud G; Bui BN; Delva R; Bay JO; Fléchon A; Geoffrois L; Caty A; Soares DG; de Revel T; Fizazi K; Gligorov J; Micléa JM; Dubot C; Provent S; Temby I; Gaulet M; Horn E; Brindel I; Lotz JP
Ann Oncol; 2014 Sep; 25(9):1775-1782. PubMed ID: 24894084
[TBL] [Abstract][Full Text] [Related]
4. Multicentric phase II trial of TI-CE high-dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors.
Chevreau C; Massard C; Flechon A; Delva R; Gravis G; Lotz JP; Bay JO; Gross-Goupil M; Fizazi K; Mourey L; Paci A; Guitton J; Thomas F; Lelièvre B; Ciccolini J; Moeung S; Gallois Y; Olivier P; Culine S; Filleron T; Chatelut E
Cancer Med; 2021 Apr; 10(7):2250-2258. PubMed ID: 33675184
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors.
Nieto Y; Tu SM; Bassett R; Jones RB; Gulbis AM; Tannir N; Kingham A; Ledesma C; Margolin K; Holmberg L; Champlin R; Pagliaro L
Ann Oncol; 2015 Oct; 26(10):2125-32. PubMed ID: 26199392
[TBL] [Abstract][Full Text] [Related]
6. High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Salvage Therapy of Relapsed/Refractory Germ Cell Tumors: A Single-Center Experience.
Yildiran Keskin GS; Erturk I; Aykan MB; Acar R; Dumludag A; Topal A; Koseoglu C; Kuzu OF; Ornek E; Karadurmus N
Oncol Res Treat; 2024; 47(6):262-272. PubMed ID: 38583428
[TBL] [Abstract][Full Text] [Related]
7. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients.
Motzer RJ; Mazumdar M; Sheinfeld J; Bajorin DF; Macapinlac HA; Bains M; Reich L; Flombaum C; Mariani T; Tong WP; Bosl GJ
J Clin Oncol; 2000 Mar; 18(6):1173-80. PubMed ID: 10715285
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome of salvage high-dose chemotherapy in patients with germ cell tumor with poor prognostic features.
De Giorgi U; Rosti G; Salvioni R; Papiani G; Ballardini M; Pizzocaro G; Marangolo M
Urol Oncol; 2011; 29(3):284-90. PubMed ID: 19556152
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of relapsed/refractory extracranial germ cell tumors treated on conventional salvage chemotherapy without stem cell rescue: Experience from a tertiary cancer center.
Ramanathan S; Prasad M; Vora T; Badira CP; Kembhavi S; Ramadwar M; Khanna N; Laskar S; Muckaden MA; Qureshi S; Banavali S; Chinnaswamy G
Pediatr Blood Cancer; 2023 Apr; 70(4):e30179. PubMed ID: 36645132
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer.
Margolin KA; Doroshow JH; Frankel P; Chow W; Leong LA; Lim D; McNamara M; Morgan RJ; Shibata S; Somlo G; Twardowski P; Yen Y; Kogut N; Schriber J; Alvarnas J; Stalter S
Biol Blood Marrow Transplant; 2005 Nov; 11(11):903-11. PubMed ID: 16275593
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, and Carboplatin (TI-TIC) With Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell Tumors.
Feldman DR; Glezerman I; Patil S; Van Alstine L; Bajorin DF; Fischer P; Hughes A; Sheinfeld J; Bains M; Reich L; Woo K; Giralt S; Bosl GJ; Motzer RJ
Clin Genitourin Cancer; 2015 Oct; 13(5):453-60. PubMed ID: 26072101
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of combined modality therapy for patients with stage III or IV mediastinal malignant germ cell tumors.
Kuwano H; Tsuchiya T; Murayama T; Sano A; Nagayama K; Yoshida Y; Murakawa T; Nakajima J
Surg Today; 2014 Mar; 44(3):499-504. PubMed ID: 23553421
[TBL] [Abstract][Full Text] [Related]
13. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
14. Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial.
Lotz JP; Bui B; Gomez F; Théodore C; Caty A; Fizazi K; Gravis G; Delva R; Peny J; Viens P; Duclos B; De Revel T; Curé H; Gligorov J; Guillemaut S; Ségura C; Provent S; Droz JP; Culine S; Biron P;
Ann Oncol; 2005 Mar; 16(3):411-8. PubMed ID: 15659420
[TBL] [Abstract][Full Text] [Related]
15. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database.
Lorch A; Bascoul-Mollevi C; Kramar A; Einhorn L; Necchi A; Massard C; De Giorgi U; Fléchon A; Margolin K; Lotz JP; Germà-Lluch JR; Powles T; Kollmannsberger C; Beyer J
J Clin Oncol; 2011 Jun; 29(16):2178-84. PubMed ID: 21444870
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group.
Hartmann JT; Gauler T; Metzner B; Gerl A; Casper J; Rick O; Horger M; Schleicher J; Derigs G; Mayer-Steinacker R; Beyer J; Kuczyk MA; Bokemeyer C;
J Clin Oncol; 2007 Dec; 25(36):5742-7. PubMed ID: 18089869
[TBL] [Abstract][Full Text] [Related]
17. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.
Siegert W; Beyer J; Strohscheer I; Baurmann H; Oettle H; Zingsem J; Zimmermann R; Bokemeyer C; Schmoll HJ; Huhn D
J Clin Oncol; 1994 Jun; 12(6):1223-31. PubMed ID: 7911158
[TBL] [Abstract][Full Text] [Related]
18. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support.
Margolin K; Doroshow JH; Ahn C; Hamasaki V; Leong L; Morgan R; Raschko J; Shibata S; Somlo G; Tetef M
J Clin Oncol; 1996 Oct; 14(10):2631-7. PubMed ID: 8874321
[TBL] [Abstract][Full Text] [Related]
19. High-dose chemotherapy followed by hematological support: experience in the treatment of germ cell tumors.
Pico JL; Fadel E; Ibrahim A; Bourhis JH; Droz JP
Bull Cancer; 1995; 82 Suppl 1():56s-60s. PubMed ID: 7542945
[TBL] [Abstract][Full Text] [Related]
20. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer.
Rick O; Bokemeyer C; Beyer J; Hartmann JT; Schwella N; Kingreen D; Neureither S; Metzner B; Casper J; Wandt H; Hartmann F; Schmoll HJ; Derigs G; Gerl A; Berdel WE; Kanz L; Siegert W
J Clin Oncol; 2001 Jan; 19(1):81-8. PubMed ID: 11134198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]